Spots Global Cancer Trial Database for Detection and Pathogenesis of Novel Protein F

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Detection and Pathogenesis of Novel Protein F

Official Title: Detection and Pathogenesis of Novel Protein F

Study ID: NCT04338386

Conditions

Cardiac Disease

Multiple Myeloma

Interventions

Study Description

Brief Summary: From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.

Detailed Description: Protein F screening was performed on anticoagulant blood plasma with heparin Lithium or blood serum by in-house turbidimetric method in Automatic biochemical analyzer. All patients were followed-up for 3 years by telephones, routine appointment out-patient clinic or returning visit.